Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $116 Price Target
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating
BofA Securities analyst Tazeen Ahmad maintains $Ultragenyx Pharmaceutical(RARE.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 53.0% and a total average return
Stifel Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $127
Stifel analyst Dae Gon Ha maintains $Ultragenyx Pharmaceutical(RARE.US)$ with a buy rating, and maintains the target price at $127.According to TipRanks data, the analyst has a success rate of 46.3%
Stifel Nicolaus Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks To Buy Now
Optimistic Investors Push Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Up 26% But Growth Is Lacking
Ultragenyx to Participate in Investor Conferences in September
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Ultragenyx Pharmaceutical Inc : Citigroup Cuts Target Price to $111 From $118
Don't Ignore The Insider Selling In Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Insider Sold Shares Worth $1,003,400, According to a Recent SEC Filing
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $81
Truist Financial Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating
Truist Financial analyst Joon Lee maintains $Ultragenyx Pharmaceutical(RARE.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 49.8% and a total average return of 21.
Express News | Ultragenyx Pharmaceutical Inc : Guggenheim Raises Target Price to $64 From $55
Barclays Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $81
Barclays analyst Gena Wang maintains $Ultragenyx Pharmaceutical(RARE.US)$ with a buy rating, and maintains the target price at $81.According to TipRanks data, the analyst has a success rate of 47.3%
Ultragenyx Pharmaceutical: A Strong Buy on Robust Financial and Pipeline Progress
Ultragenyx Pharmaceutical (RARE) Receives a Buy From Barclays
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $67 to $127
On Aug 03, major Wall Street analysts update their ratings for $Ultragenyx Pharmaceutical(RARE.US)$, with price targets ranging from $67 to $127.Morgan Stanley analyst Jeffrey Hung maintains with a
Ultragenyx Pharmaceutical | 10-Q: Q2 2024 Earnings Report
Ultragenyx Pharma Price Target Raised to $75.00/Share From $72.00 by Wells Fargo